

DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE
PRECISION DIAGNOSTICS – INHERITED DISEASE

Master List of References

ACADVL

1. Mathur A, Sims HF, Gopalakrishnan D et al. Molecular heterogeneity in very-long-chain acyl-CoA dehydrogenase deficiency causing pediatric cardiomyopathy and sudden death. *Circulation* 1999;99:1337-43. [PMID: 10077518]
2. Vianey-Saban C, Divry P, Brivet M et al. Mitochondrial very-long-chain acyl-coenzyme A dehydrogenase deficiency: Clinical characteristics and diagnostic considerations in 30 patients. *Clin Chim Acta* 1998;269:43-62. [PMID: 9498103]

AR

1. Giagulli VA, Carbone MD, De Pergola G, et al. Could androgen receptor gene CAG tract polymorphism affect spermatogenesis in men with idiopathic infertility? *J Assist Reprod Genet* 2014;31(6):689-97. [PMID: 24691874]
2. Gottlieb B, Beitel LK, Nadarajah A, et al. The androgen receptor gene mutations database (ARDB): 2012 update. *Hum Mutat.* 2012;33:887-94. [PMID: 22334387]

Array CGH

1. Boone PM, Bacino CA, Shaw CA et al., Detection of clinically relevant exonic copy-number changes by array CGH. *Hum Mutat* 2010;31(12):1326-1342. [PMID: 20848651]

CFTR

1. Collaco AM, Geibel P, Lee BS et al. Functional vacuolar ATPase (V-ATPase) proton pumps traffic to the enterocyte brush border membrane and require CFTR. *Am J Physiol Cell Physiol* 2013;305(9):C981-996. [PMID: 23986201]
2. Lu S, Yang X, Li X et al. Different cystic fibrosis transmembrane conductance regulator mutations in Chinese men with congenital bilateral absence of vas deferens and other acquired obstructive azoospermia. *Urology* 2013;82(4):824-828. [PMID: 23953609]
3. Sosnay PR, Siklosi KR, Van Goor F et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. *Nat Genet* 2013;45(10):1160-1167. [PMID: 23974870]
4. Schrijver I, Pique L, Graham S et al. The Spectrum of CFTR Variants in Nonwhite Cystic Fibrosis Patients: Implications for Molecular Diagnostics. *J Mol Diagn* 2016;18(1):39-50 [PMID:26708955]
5. Quemener S, Chen JM, Chuzhanova N et al. Complete ascertainment of intragenic copy number mutations (CNMs) in the CFTR gene and its implications for CNM formation at other autosomal loci. *Human Mutat* 2010;31(4):421-428. [PMID: 20052766]
6. de Becdelièvre A, Costa C, LeFloch A, et al. Notable contribution of large CFTR gene rearrangements to the diagnosis of cystic fibrosis in fetuses with bowel anomalies. *Eur J Hum Genet.* 2010;18(10):1166-1169. [PMID: 20512161]

CFTR 23-MUTATION TEST

1. Grody WW, Cutting GR, Klinger KW, et. al. Subcommittee on Cystic Fibrosis Screening, Accreditation of Genetic Services Committee, ACMG. American College of Medical Genetics. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. *Genet Med.* 2001;3(2):149-54 [PMID: 11280952]
2. Watson MS, Cutting GR, Desnick RJ et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. *Genet Med.* 2004;6(5):387-391. [PMID: 15371902]
3. Palomaki GE, FitzSimmons SC, Haddow JE. Clinical sensitivity of prenatal screening for cystic fibrosis via CFTR carrier testing in a United States panethnic population. *Genet Med.* 2004;6(5):405-414. [PMID: 15371905]

GA1

1. Goodman SI, Stein DE, Schlesinger S et al. Glutaryl-CoA dehydrogenase mutations in glutaric acidemia (Type 1): Review and report of thirty novel mutations. *Human Mutation* 1998;12:141-144. [PMID: 9711871]
2. Kulkens S, Harting I, Sauer S et al. Late-onset neurologic disease in Glutaryl-CoA dehydrogenase deficiency. *Neurology* 2005;64(12):2142-2144. [PMID: 15985591]
3. Morton DH, Bennett MJ, Seargeant LE et al. Glutaric aciduria type I: a common cause of episodic encephalopathy and spastic paralysis in the Amish of Lancaster County, Pennsylvania. *Hum Genet* 1991;102(4):452-458 [PMID: 1951469]
4. Strauss KA, Puffenberger EG, Robinson DL et al. Type I glutaric aciduria, part 1: natural history of 77 patients. *Am J Med Genet Part C: Seminars in Medical Genetics* 2003; 21C(1):38-52. [PMID: 12888985]

GNAI3

1. Masotti C, Oliveira KG, Poener F et al. Auriculo-condylar syndrome: mapping of a first locus and evidence for genetic heterogeneity. *Eur J Hum Genet* 2008;16(2):145-152. [PMID: 18000524]
2. Rieder MJ, Green GE, Park SS et al. A Human Homeotic Transformation Resulting from Mutations in PLCB4 and GNAI3 Causes Auriculocondylar Syndrome. *Am J Hum Genet* 2012;90(5):907-914. [PMID: 22560091]
3. Gordon CT, Vuillot A, Marlin S et al. Heterogeneity of mutational mechanisms and modes of inheritance in auriculocondylar syndrome. *J Med Genet* 2013;50:174-186. [PubMed: 23315542]

MMA PANEL

1. Gulati S, Baker P, Li YN et al. Defects in human methionine synthase in cblG patients. *Hum Molec Genet* 1996;5: 1859-1865. [PMID: 8968736]
2. Aminoff M, Carter JE, Chadwick RB et al. Mutations in CUBN, encoding the intrinsic factor-vitamin B12 receptor, cubilin, cause hereditary megaloblastic anaemia 1. *Nature Genet* 1999;21:309-313. [PMID: 10080186]
3. Kraus JP, Janosik M, Kozich V et al. Cystathionine beta-synthase mutations in homocystinuria. *Hum Mutat* 1999;13:362-375. [PMID:10338090]
4. Wilson A, Leclerc D, Rosenblatt DS et al. Molecular basis for methionine synthase reductase deficiency in patients belonging to the cblE complementation group of disorders in folate/cobalamin metabolism. *Hum Molec Genet* 1999;8:2009-2016. [PMID: 10484769]
5. Tanner SM Li Z, Perko JD et al. Hereditary juvenile cobalamin deficiency caused by mutations in the intrinsic factor gene. *PNAS* 2005;102(11):4130-4133. [PMID: 15738392]
6. Tanner SM et al., Inherited cobalamin malabsorption. Mutations in three genes reveal functional and ethnic patterns. *Orphanet J Rare Dis* (2012) 7:56. [PMID: 22929189]
7. Ferrand A, Siu VM, Rupar CA et al. Biochemical and Hematologic Manifestations of Gastric Intrinsic Factor (GIF) Deficiency: A Treatable Cause of B12 Deficiency in the Old Order Mennonite Population of Southwestern Ontario. *JIMD Reports* 2015;18:69-77. [PMID: 25308559]
8. Tanner SM, Aminoff M, Wright FA et al. Amnionless, essential for mouse gastrulation, is mutated in recessive hereditary megaloblastic anemia. *Nature Genet* 2003;33:426-429. [PMID: 12590260]
9. Gordon MM, Brada N, Remacha A et al. A genetic polymorphism in the coding region of the gastric intrinsic factor gene (GIF) is associated with congenital intrinsic factor deficiency. *Hum Mutat* 2004; 23:85-91. [PMID: 14695536]
10. Manoli I, Sloan J and Venditti CP. Isolated Methylmalonic Acidemia Updated January 7, 2016]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. *GeneReviews*® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1231/>.
11. Ostergaard E, Hansen FJ, Sorensen Net al. Mitochondrial encephalomyopathy with elevated methylmalonic acid is caused by SUCLA2 mutations. *Brain* 2007;130:853-861. [PMID: 17287286]

NKH

1. Van Hove J, Coughlin C II, Schärer G. Glycine encephalopathy. 2002. *GeneReviews*®. [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016. 2002 Nov 14 [updated 2013 Jul 11]. [PubMed ID:20301531]
2. Applegarth DA and Toone JR. Glycine encephalopathy (Nonketotic Hyperglycinemia): Review and update. *J Inherit Metab Dis* 2004;27:417-422. [PMID: 15272469]
3. Kanno J, Hutchin T, Kamada F et al. Genomic deletion within GLDC is a major cause of non-ketotic hyperglycinemia. *J. Med Genet* 2007;44(3):e69. [PMID: 17361008]
4. Kure S, Kato K, Dinopoulos A et al. Comprehensive mutation analysis of GLDC, AMT and GCSH in Nonketotic Hyperglycinemia. *Hum Mutat* 2006;27(4):343-352. [PMID: 16450403]
5. Swanson MA, Coughlin CR Jr, Schärer GH et al. Biochemical and molecular predictors for prognosis in nonketotic hyperglycinemia. *Ann Neurol*. 2015;78(4):606-18. [PMID: 26179960]
6. Coughlin II CR, Swanson MA, Kronquist KE et al. The genetic basis of classic nonketotic hyperglycinemia due to mutations in *GLDC* and *AMT*. *Genet Med*. 2017;19:104-111. [PMID: 27362913]

OCA Panel

1. Hutton SM, Spritz RA. A comprehensive genetic study of autosomal recessive ocular albinism in Caucasian patients. *Investigative Ophthalmology and Visual Science* 2008;49:868-872. [PMID: 18326704]
2. Tripathi RK, Strunk KM, Giebel LB et al. Tyrosinase gene mutations in type I (tyrosinase-deficient) oculocutaneous albinism define two clusters of missense substitutions. *Am. J. Med. Genet*. 1992;43:865-871. [PMID: 1642278]
3. Morice-Picard F, Lasseaux E, François S et al SLC24A5 Mutations Are Associated with Non-Syndromic Oculocutaneous Albinism. *J Invest Dermatol* 2014;134:568-571. [PMID: 23985994]
4. Chiang PW, Spector E, Tsai ACH. Oculocutaneous albinism spectrum. *Am J Med Genet A*. 2009;149A:1590-1591. [PMID: 19533789]
5. Oetting WS and King RA. Molecular basis of albinism: mutations and polymorphisms of pigmentation genes associated with albinism. *Hum Mutat* 1999;13:99-115. [PMID: 10094567]
6. Morice-Picard F, Lasseaux E, Cailley D et al. High-resolution array-CGH in patients with oculocutaneous albinism identifies new deletions of the TYR, OCA2, and SLC45A2 genes and a complex rearrangement of the OCA2 gene. *Pigment Cell and Melanoma Research* 2013;27:59-71. [PMID: 24118800]
7. Simeonov DR, Wang X, Wang C et al. DNA variations in oculocutaneous albinism: an updated mutation list and current outstanding issues in molecular diagnostics. *Hum Mutat* 2013;34:827-35. [PMID: 23504663]

POLG

1. Chan SS and Copeland WC. DNA polymerase gamma and mitochondrial disease: understanding the consequence of POLG mutations. *Biochim Biophys Acta* 2009;1787(5):312-319. [PMID: 19010300]
2. Cohen B, Chinnery PF, and Copeland WC. 2010 POLG-related disorders. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, editors. *Source GeneReviews*® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016. 2010 Mar 16 [updated 2014 Dec 18]. [PMID: 20301791]
3. Compton AG, Troedson C, Wilson M et al. Application of oligonucleotide array CGH in the detection of a large intragenic deletion in POLG associated with Alpers Syndrome. *Mitochondrion* 2010;11(1):104-107. [PMID: 20708716]
4. Tang S, Wang J, Lee NC et al. Mitochondrial DNA polymerase gamma mutations: an ever expanding molecular and clinical spectrum. *J Med Genet* 2011;48(10):669-681. [PMID: 21880868]

PTEN

1. Teresi RE, Zbuk KM, Pezzolesi MG et al. Cowden Syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation. *Am J Hum Genet* 2007;81:756-767. [PMID: 17847000]
2. Lintas C and Persico AM. Autistic phenotypes and genetic testing: state-of-the-art for the clinical geneticist. *J Med Genet* 2009;46:1-8. [PMID: 18728070]
3. Mester J and Eng C. Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome. *Genet Med* 2012;14(9):819-822. [PMID: 22595938]

Quantitative Real-Time PCR

1. D'Haene B, Vandesompele J, Hellemans J. Accurate and objective copy number profiling using real-time quantitative PCR. *Methods* 2010;50: 262-270. [PMID: 20060046]

Rasopathies Panel

1. Tartaglia M and Gelb BD. Noonan syndrome and related disorders: genetics and pathogenesis. *Ann Rev Genomics Hum Genet.* 2005;6:45-68. [PMID: 16124853]
2. Neumann TE, Allanson J, Kavamura I et al. Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome. *Eur J Hum Genet.* 2009;17(4):420-425. [PMID: 18854871]
3. Rodriguez-Viciano P, Tetsu O, Tidyman WE et al. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. *Science.* 2006;311(5765):1287-90. [PMID: 16439621]
4. Gripp KW. Tumor predisposition in Costello syndrome. *Am J Med Genet C Semin Med Genet.* 2005;137C(1):72-7. [PMID: 16010679]
5. Gripp KW, Lin AE, Stabley DL et al. HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. *Am J Med Genet A.* 2006;140(1):1-7. [PMID: 16329078]
6. Kerr B, Delrue MA, Sigaudy S et al. Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases. *J Med Genet.* 2006;43(5):401-405. [PMID: 16443854]
7. Messiaen L, Yao S, Brems H et al. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. *Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. JAMA.* 2009;302(19):2111-2118 [PMID: 19920235]
8. Tartaglia M and Gelb BD. Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. *Ann N Y Acad Sci.* 2010;1214:99-121. PMID: 20958325]
9. Aoki Y, Niihori T, Inoue S et al. Recent advances in RASopathies. *J Hum Genet.* 2016;61(1):33-39. [PMID: 26446362]
10. Lin AE, Alexander ME, Colan SD et al. Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello syndrome: a Ras/MAPK pathway syndrome. *Am J Med. Genet.* 2011;155A:486-507. [PMID: 21344638]

Rasopathies Panel/ A2ML1

11. Vissers LE, Bonetti M, Paardekooper Overman J et al. Heterozygous germline mutations in A2ML1 are associated with a disorder clinically related to Noonan syndrome. *Eur J Hum Genet.* 2015;23:317-324. [PMID: 24939586]
12. Galliano MF, Toulza E, Jonca N et al. Binding of alpha2ML1 to the low density lipoprotein receptor-related protein 1 (LRP1) reveals a new role for LRP1 in the human epidermis. *PLoS ONE* 2008;3:e2729. [PMID: 18648652]

Rasopathies Panel/ ACTB and ACTG1

13. Rivière JB, van Bon BW, Hoischen A et al. De novo mutations in the actin genes ACTB and ACTG1 cause Baraitser-Winter syndrome. *Nat Genet.* 2012;44(4):440-444. [PMID: 22366783]

Rasopathies Panel/ BRAF

14. Niihori T, Aoki Y, Narumi Y et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. *Nat Genet.* 2006;38(3):294-296. [PMID: 16474404]
15. Sarkozy A, Carta C, Moretti S Et al. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. *Hum Mutat.* 2009;30(4):695-702. [PMID: 20543203]

Rasopathies Panel/ CBL

16. Martinelli S, De Luca A, Stellacci E et al. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. *Am J Hum Genet.* 2010;87(2):250-257. [PMID: 20619386]
17. Niemeyer CM, Kang MW, Shin DH et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. *Nat Genet.* 2010;42:794-800. [PMID: 20694012]
18. Perez B, Mechinaud F, Galambri C et al. Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia. *J Med Genet.* 2010;47:686-691. [PMID: 20543203]

Rasopathies Panel/ HRAS

19. Aoki Y, Niihori T, Kawame H et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. *Nat Genet.* 2005;37(10):1038-1040. [PMID: 16170316]
20. Estep AL, Tidyman WE, Teitell MA et al. HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. *Am J Med Genet A.* 2006;140(1):8-16. [PMID: 16372351]

Rasopathies Panel/ KRAS

21. Schubert S, Zenker M, Rowe SL et al. Germline KRAS mutations cause Noonan syndrome. *Nat Genet.* 2006;38(3):331-336. [PMID: 16474405]
22. Carta C, Pantaleoni F, Bocchinfuso G et al. Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. *Am J Hum Genet.* 2006 Jul;79(1):129-135. [PMID: 16773572]
23. Niihori T, Aoki Y, Narumi Y et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. *Nat Genet.* 2006;38(3):294-296. [PMID: 16474404]
24. Cirstea IC, Kutsche K, Dvorsky R et al. A restricted spectrum of NRAS mutations causes Noonan syndrome. *Nat Genet.* 2010;42(1):27-29. [PMID: 19966803]
25. Schubert S, Zenker M, Rowe SL et al. Germline KRAS mutations cause Noonan syndrome. *Nat Genet.* 2006;38: 331-336. [PMID: 16474405]

Rasopathies Panel/ LZTR1

26. Yamamoto GL, Aguena M, Gos M et al. Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome. *J Med Genet.* 2015;52:413-421. [PMID: 25795793]
27. Piotrowski A, Xie J, Liu YF et al. Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. *Nat Genet.* 2014;46:182-187. [PMID: 24362817]

Rasopathies Panel/ MAP2K1 and MAP2K2

28. Chen PC, Yin J, Yu HW et al. Next-generation sequencing identifies rare variants associated with Noonan syndrome. *Proc Natl Acad Sci U S A.* 2014;111(31):11473-8. [PMID: 25049390]
29. Croonen EA, Nillesen W, Schrandt C et al. Noonan syndrome: comparing mutation-positive with mutation-negative Dutch patients. *Mol Syndromol.* 2013;4(5):227-234. [PMID: 23885229]
30. Takenouchi T, Shimizu A, Torii C et al. Multiple café au lait spots in familial patients with MAP2K2 mutation. *Am J Med Genet A.* 2014;164A(2):392-396 [PMID: 24311457]
31. Nishi E, Mizuno S, Nanjo Y et al. A novel heterozygous MAP2K1 mutation in a patient with Noonan syndrome with multiple lentiginos. *Am J Med Genet A.* 2015 Feb;167A(2):407-11. [PMID: 25423878]

Rasopathies Panel/ NRAS

32. Cirstea IC, Kutsche K, Dvorsky R et al. A restricted spectrum of NRAS mutations causes Noonan syndrome. *Nat Genet.* 2010;42:27-29. [PMID: 19966803]
33. Ekvall S, Wilbe M, Dahlgren J et al. Mutation in NRAS in familial Noonan syndrome--case report and review of the literature. *BMC Med Genet.* 2015;16:95. [PMID: 26467218].

Rasopathies Panel/ PPP1CB

34. Gripp KW, Aldinger KA, Bennett JT et al. A novel rasopathy caused by recurrent de novo missense mutations in PPP1CB closely resembles Noonan syndrome with loose anagen hair. *Am J Med Genet A.* 2016;170(9):2237-2247. [PMID: 27264673]
35. Bertola D, Yamamoto G, Buscarilli M et al. The recurrent PPP1CB mutation p.Pro49Arg in an additional Noonan-like syndrome individual: Broadening the clinical phenotype. *Am J Med Genet A.* 2017;173(3):824-828. [PMID: 28211982]
36. Zambrano RM, Marble M, Chalew SA et al. Further evidence that variants in PPP1CB cause a rasopathy similar to Noonan syndrome with loose anagen hair. *Am J Med Genet A.* 2017;173(2):565-567. [PMID: 27868344]

Rasopathies Panel/ PTPN11

37. Tartaglia M, Kalidas K, Shaw A et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. *Am J Hum Genet.* 2002;70(6):1555-1563. [PMID: 11992261]
38. Tartaglia M., Mehler E L, Goldberg R et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. *Nat Genet.* 2000;29:465-468. [PMID: 11704759]
39. Kontaridis MI, Swanson KD, David FS et al. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. *J Biol Chem.* 2006;281:6785-6792. [PMID: 16377799]
40. Tartaglia M, Martinelli S, Stella L et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. *Am J Hum Genet.* 2006;78:279-290. [PMID: 16358218]

Rasopathies Panel/ RAF1

41. Pandit B, Sarkozy A, Pennacchio LA et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. *Nat Genet.* 2007;39(8):1007-1012. [PMID: 17603483]
42. Razzaque MA, Nishizawa T, Komoike Y et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. *Nat Genet.* 2007;39(8):1013-1017. [PMID: 17603482]
43. Kobayashi T, Aoki Y, Niihori T et al. Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation. *Hum Mutat.* 2010;31:284-294. [PMID: 20052757] *Hum Mutat.* 2010;31:284-294. [PMID: 20052757]

Rasopathies Panel/ RASA2

44. Eerola I, Boon LM, Mulliken JB et al. Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. *Am J Hum Genet.* 2003;73:1240-1249. [PMID: 14639529]

Rasopathies Panel/ RIT1

45. Gos M, Fahiminiya S, Poznański J et al., Contribution of RIT1 mutations to the pathogenesis of Noonan syndrome: four new cases and further evidence of heterogeneity. *Am J Med Genet A.* 2014;164A(9):2310-2316. [PMID: 24939608]
46. Bertola DR, Yamamoto GL, Almeida TF et al. Further evidence of the importance of RIT1 in Noonan syndrome. *Am J Med Genet A.* 2014;164A(11):2952-2957. [PMID: 25124994]
47. Aoki Y, Niihori T, Banjo T, et al. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. *Am J Hum Genet.* 2013;93(1):173-180. [PMID: 23791108]
48. Gomez-Segui I, Makishima H, Jerez A et al. Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies. *Leukemia* 2013;27:1943-1946. [PMID: 23765226]
49. Chen PC, Yin J, Yu HW et al. Next-generation sequencing identifies rare variants associated with Noonan syndrome. *Proc Natl Acad Sci U S A.* 2014;111(31):11473-8. [PMID: 25049390]

Rasopathies Panel/ RRAS

50. Flex E, Jaiswal M, Pantaleoni F et al. Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis. *Hum Mol Genet.* 2014;23:4315-4327. [PMID: 24705357]

Rasopathies Panel/ SHOC2

51. Cordeddu V, Di Schiavi E, Pennacchio LA et al. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. *Nat Genet.* 2009;41(9):1022-1026. [PMID: 19684605]
52. Komatsuzaki S, Aoki Y, Niihori T et al. Mutation analysis of the SHOC2 gene in Noonan-like syndrome and in hematologic malignancies. *J Hum Genet.* 2010;55: 801-809. [PMID: 20882035]

Rasopathies Panel/ SOS 1

53. Roberts AE, Araki T, Swanson KD et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. *Nat Genet.* 2007 Jan;39(1):70-74. [PMID: 17143285]
54. Tartaglia M, Pennacchio LA, Zhao C et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. *Nat Genet.* 2007;39(1):75-79. [PMID: 17143282]
55. Tartaglia M, Pennacchio LA, Zhao, C et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. *Nat Genet.* 2007;39:75-79. [PMID: 17143282]

Rasopathies Panel/ SOS2

56. Yamamoto GL, Aguen M, Gos M et al. Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome. *J Med Genet.* 2015;52:413-421. [PMID: 25795793]

Rasopathies Panel/ SPRED1

57. Brems H, Chmara M, Sahbatou M et al. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. *Nat Genet.* 2007;39(9):1120-1126. [PMID: 17704776]
58. Muram-Zborovski TM, Stevenson DA, Viskochil DH et al. SPRED 1 mutations in a neurofibromatosis clinic. *J Child Neurol.* 2010 Oct;25(10):1203-1209. [PMID: 20179001]
59. Pasmant E, Sabbagh A, Hanna N et al. SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. *J Med Genet.* 2009 Jul;46(7):425-430. [PMID: 19366998]
60. Spurlock G, Bennett E, Chuzhanova N et al. SPRED1 mutations (Legius syndrome): another clinically useful genotype for dissecting the neurofibromatosis type 1 phenotype. *Med Genet.* 2009;46(7):431-7. [PMID: 19443465]
61. Brems H, Pasmant E, Van Minkelen R et al. Review and update of SPRED1 mutations causing Legius syndrome. *Hum Mutat.* 2012; 33:1538-1546. [PMID: 22753041]

SRY

1. Mohnach L, Fechner P, and Keegan CE. Nonsyndromic disorders of Testicular development. 2016 In GeneReviews® [Internet]. Pagon RA, Adam MP, Ardinger HH, et al., editors. Seattle (WA): University of Washington, Seattle; 1993-2016. Available at <http://www.genetests.org>. Accessed [June 2016].
2. Sarafoglou K, Ostrer H. Clinical review 111: familial sex reversal: a review. *J Clin Endocrinol Metab* 2000;85:483-493. [PMID: 10690846].
3. Ostrer H. Disorders of sex development (DSDs): an update. *J Clin Endocrinol Metab.* 2014;99:1503-1509. [PMID: 24758178]
4. Cameron FJ, Sinclair AH. Mutations in SRY and SOX9: testis-determining genes. *Hum Mutat.* 1997;9:388-395. [PMID: 9143916]
5. Scherer G, Held M, Erdel M et al. Three novel SRY mutations in XY gonadal dysgenesis and the enigma of XY gonadal dysgenesis cases without SRY mutations. *Cytogenet Cell Genet* 1998;80(1-4):188-192. [PMID: 9678356]
6. White S, Ohnesorg T, Notini A, et al. Copy number variation in patients with disorders of sex development due to 46,XY gonadal dysgenesis. *PLoS One.* 2011;6:e17793. [PMID: 21408189]

WT1

1. Little, M., Wells, C. A clinical overview of WT1 gene mutations. *Hum Mutat* 1197;9:209-225. [PMID: 9090524]
2. Schumacher, V., Scharer, K., Wuhl, E. et al. Spectrum of early onset nephrotic syndrome associated with WT1 missense mutations. *Kidney Int* 1998;53:1594-1600. [PMID: 9607189]
3. Royer-Pokora, B., Beier, M., Henzler, M. et al. Twenty-four new cases of WT1 germline mutations and review of the literature: genotype/phenotype correlations for Wilms tumor development. *Am J Med Genet* 2004;127A:249-257. [PMID: 15150775]